Skip to contentP
Palvella Therapeutics, Inc.
P
PVLAPalvella Therapeutics, Inc. Q2 2023 · 10-Q
Revenue$20.06M$20.06M+442.3% vs Q2 2022 Net Income$3.98M$3.98MN/M vs Q2 2022 EPS Diluted$3.62$3.62N/M vs Q2 2022 Operating Income$2,063,000N/M Operating Cash Flow
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Palvella Therapeutics, Inc. · CIK 1583648 · Engraved from SEC EDGAR
derived
Free Cash Flowderived-$13,498,000N/M Margins · derivedOperating margin10.3%+343.7 pt vs Q2 2022
Net margin19.8%+299.4 pt vs Q2 2022
ended Jun 30, 2023 · filed Aug 10, 2023 · 41 d after period end